S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

RxSight Stock Forecast, Price & News

+0.28 (+2.58%)
(As of 12/1/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
90,064 shs
Average Volume
117,454 shs
Market Capitalization
$304.45 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RXST News and Ratings via Email

Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter.

RxSight logo

About RxSight

RxSight Inc. is a commercial-stage medical technology company focuses on patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens(R), RxSight Light Delivery Device and accessories. RxSight Inc. is based in ALISO VIEJO, Calif.


RxSight to Participate in the Ophthalmology Day at BTIG
November 18, 2021 |  finance.yahoo.com
RxSight, Inc. (RXST)
November 17, 2021 |  finance.yahoo.com
SVB Leerink Reaffirms "Buy" Rating for RxSight (NASDAQ:RXST)
November 14, 2021 |  americanbankingnews.com
RxSight, Inc. (RXST) Q3 2021 Earnings Call Transcript
November 11, 2021 |  finance.yahoo.com
Reviewing National Vision (NASDAQ:EYE) & RxSight (NASDAQ:RXST)
November 11, 2021 |  americanbankingnews.com
RxSight Reports Third Quarter 2021 Financial Results
November 10, 2021 |  finance.yahoo.com
RxSight Reports Second Quarter 2021 Financial Results
September 9, 2021 |  finance.yahoo.com
Rxsight Inc
September 8, 2021 |  reuters.com
See More Headlines

Industry, Sector and Symbol

Ophthalmic goods
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$5.52 per share


Pretax Margin




Free Float
Market Cap
$304.45 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.16 out of 5 stars

Medical Sector

436th out of 1,392 stocks

Ophthalmic Goods Industry

3rd out of 5 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

RxSight (NASDAQ:RXST) Frequently Asked Questions

Is RxSight a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RxSight in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RxSight stock.
View analyst ratings for RxSight
or view top-rated stocks.

When is RxSight's next earnings date?

RxSight is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for RxSight

How were RxSight's earnings last quarter?

RxSight Inc (NASDAQ:RXST) announced its earnings results on Wednesday, November, 10th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by $0.04. The firm earned $5.79 million during the quarter, compared to analysts' expectations of $5.24 million.
View RxSight's earnings history

What guidance has RxSight issued on next quarter's earnings?

RxSight updated its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $21 million-$21.40 million, compared to the consensus revenue estimate of $20.87 million.

What price target have analysts set for RXST?

5 analysts have issued 12 month price objectives for RxSight's stock. Their forecasts range from $16.00 to $28.00. On average, they anticipate RxSight's stock price to reach $20.20 in the next year. This suggests a possible upside of 81.5% from the stock's current price.
View analysts' price targets for RxSight
or view top-rated stocks among Wall Street analysts.

When did RxSight IPO?

(RXST) raised $125 million in an IPO on Friday, July 30th 2021. The company issued 7,350,000 shares at a price of $16.00-$18.00 per share.

What is RxSight's stock symbol?

RxSight trades on the NASDAQ under the ticker symbol "RXST."

When does RxSight's lock-up period expire?

RxSight's lock-up period expires on Wednesday, January 26th. RxSight had issued 7,350,000 shares in its IPO on July 30th. The total size of the offering was $117,600,000 based on an initial share price of $16.00. After the end of RxSight's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Who are RxSight's major shareholders?

RxSight's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (11.18%), Deerfield Management Company L.P. Series C (3.30%), BlackRock Inc. (1.28%), Millennium Management LLC (1.21%), Magnetar Financial LLC (1.03%) and RTW Investments LP (0.55%).
View institutional ownership trends for RxSight

Which institutional investors are buying RxSight stock?

RXST stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Deerfield Management Company L.P. Series C, BlackRock Inc., Millennium Management LLC, Magnetar Financial LLC, RTW Investments LP, Caas Capital Management LP, and Geode Capital Management LLC.
View insider buying and selling activity for RxSight
or or view top insider-buying stocks.

How do I buy shares of RxSight?

Shares of RXST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RxSight's stock price today?

One share of RXST stock can currently be purchased for approximately $11.13.

How much money does RxSight make?

RxSight has a market capitalization of $304.45 million.

How many employees does RxSight have?

RxSight employs 2,021 workers across the globe.

What is RxSight's official website?

The official website for RxSight is www.rxsight.com.

How can I contact RxSight?

The company can be reached via phone at 949-521-7830 or via email at [email protected].

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.